Multifunctional nanorods based on self-assembly of biomimetic apolipoprotein E peptide for the treatment of Alzheimer's disease.

Published on Jun 1, 2021in Journal of Controlled Release7.727
· DOI :10.1016/J.JCONREL.2021.05.044
Shanshan Zhang (ZJNU: Zhejiang Chinese Medical University), Sajid Asghar16
Estimated H-index: 16
(GCUF: Government College University, Faisalabad)
+ 7 AuthorsYanyu Xiao22
Estimated H-index: 22
(CPU: China Pharmaceutical University)
Targeting a single molecule or a single pathway and poor drug delivery to the brain hamper the therapy of Alzheimer's disease (AD) based on abnormal metabolism of amyloid-β (Aβ). To solve these problems, we designed and synthesized a multi - strategy peptide (MOP), an ingenious apolipoprotein E mimetic peptide, which could reduce Aβ deposition via inhibiting Aβ aggregation and at the same time accelerate Aβ clearance. Meanwhile, MOP could be self-assembled into different nanostructure, thus we constructed a multifunctional delivery system (APND-3) based on MOP self-assembled nanorods (aspect ratios of 3) that was a favorable morphology to enhance the permeation across the blood brain barrier (BBB) to address the poor delivery to brain issues. Besides, the drug delivery system introduces polydopamine (PDA) and COG1410 ligand as a shell to keep the favorable morphology of core and enhance the BBB targeting efficiency. As a result, the delivery system significantly enhances the delivery of MOP to the brain, thus reducing Aβ deposition, mitigating the memory deficits, and ameliorating neurologic damage in AD model mice. Our findings suggest that our drug and carrier integrated multifunctional delivery system has the potential for AD treatment.
📖 Papers frequently viewed together
5 Citations
10 Citations
82 Citations
#1Mei Zhang (CPU: China Pharmaceutical University)H-Index: 4
#2Sajid Asghar (GCUF: Government College University, Faisalabad)H-Index: 16
Last. Yanyu Xiao (CPU: China Pharmaceutical University)H-Index: 22
view all 8 authors...
Abstract A micelle system based on hyaluronic acid (HA)-octadecylamine (OA) conjugate (HOA) functionalized with N-acetylcysteine (NAC) was constructed to yield NAC modified HOA conjugate (NHOA) for improving oral paclitaxel (PTX) delivery (PTX-NHOA). The average size of spherical PTX-NHOA micelles was 162.7 nm with a zeta potential of −27.6 mv. The encapsulation efficiency (EE) and drug loading (DL) of PTX-NHOA micelles were 92.64% and 6.96%, respectively. Additionally, NHOA micelles exihibited ...
7 CitationsSource
#1Vibhuti Agrahari (Shenandoah University)H-Index: 16
#2Pierre Alain Burnouf (AS: Academia Sinica)H-Index: 8
Last. Vivek Agrahari (EVMS: Eastern Virginia Medical School)H-Index: 6
view all 4 authors...
Abstract Nanocarriers (synthetic/cell-based have attracted enormous interest for various therapeutic indications, including neurodegenerative disorders. A broader understanding of the impact of nanomedicines design is now required to enhance their translational potential. Nanoformulations in vivo journey is significantly affected by their physicochemical properties including the size, shape, hydrophobicity, elasticity, and surface charge/chemistry/morphology, which play a role as an interface wi...
25 CitationsSource
#1Yu Yamazaki (Mayo Clinic)H-Index: 15
#2Na Zhao (Mayo Clinic)H-Index: 14
Last. Guojun Bu (Mayo Clinic)H-Index: 103
view all 5 authors...
Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*e4 allele conferring an increased risk and the APOE*e2 allele conferring a decreased risk relative to the common APOE*e3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*e4 carriers. The number of amyloid-...
208 CitationsSource
#1Jianhua Peng (LLU: Loma Linda University)H-Index: 14
#2Jinwei Pang (LLU: Loma Linda University)H-Index: 12
Last. Yong JiangH-Index: 14
view all 15 authors...
Abstract White matter injury (WMI) is associated with motor deficits and cognitive dysfunctions in subarachnoid hemorrhage (SAH) patients. Therapeutic strategy targeting WMI would likely improve the neurological outcomes after SAH. Low-density lipoprotein receptor-related protein-1 (LRP1), a scavenger receptor of apolipoprotein E (apoE), is able to modulate microglia polarization towards anti-inflammatory M2 phenotypes during inflammatory and oxidative insult. In the present study, we investigat...
27 CitationsSource
#1Daniel Mihai Teleanu (UMFCD: Carol Davila University of Medicine and Pharmacy)H-Index: 7
#2Cristina Chircov (Politehnica University of Bucharest)H-Index: 10
Last. Raluca Ioana Teleanu (UMFCD: Carol Davila University of Medicine and Pharmacy)H-Index: 7
view all 5 authors...
Pathologies of the brain, of which brain cancer, Alzheimer’s disease, Parkinson’s disease, stroke, and multiple sclerosis, are some of the most prevalent, and that presently are poorly treated due to the difficulties associated with drug development, administration, and targeting to the brain. The existence of the blood-brain barrier, a selective permeability system which acts as a local gateway against circulating foreign substances, represents the key challenge for the delivery of therapeutic ...
75 CitationsSource
#1Jorge A. Sierra-Fonseca (UTEP: University of Texas at El Paso)H-Index: 4
#2Kristin L. Gosselink (UTEP: University of Texas at El Paso)H-Index: 5
Abstract Neurodegenerative diseases are characterized by an irreversible and progressive loss of neuronal structure and function. While many alterations to normal cellular processes occur during neurodegeneration, a pathological accumulation of aggregated proteins constitutes a hallmark of several neurodegenerative disorders. Alzheimer's disease, specifically, is pathologically defined by the formation of amyloid plaques and tangles of hyperphosphorylated tau protein. Stress has emerged as an im...
25 CitationsSource
#1Na Zhao (Mayo Clinic)H-Index: 14
#2Chia Chen Liu (Mayo Clinic)H-Index: 33
Last. Guojun Bu (Ha Tai: Xiamen University)H-Index: 103
view all 4 authors...
Abstract Apolipoprotein E (apoE) is a lipid carrier in both the peripheral and the central nervous systems. Lipid-loaded apoE lipoprotein particles bind to several cell surface receptors to support membrane homeostasis and injury repair in the brain. Considering prevalence and relative risk magnitude, the e4 allele of the APOE gene is the strongest genetic risk factor for late-onset Alzheimer's disease (AD). ApoE4 contributes to AD pathogenesis by modulating multiple pathways, including but not ...
141 CitationsSource
#1Yiqun Zhou (UM: University of Miami)H-Index: 16
#2Zhili Peng (Dali University)H-Index: 18
Last. Roger M. Leblanc (UM: University of Miami)H-Index: 59
view all 4 authors...
Abstract The blood-brain barrier (BBB) is one of the most essential protection mechanisms in the central nervous system (CNS). It selectively allows individual molecules such as small lipid-soluble molecules to pass through the capillary endothelial membrane while limiting the passage of pathogens or toxins. However, this protection mechanism is also a major obstacle during disease state since it dramatically hinders the drug delivery. In recent years, various tactics have been applied to assist...
213 CitationsSource
#1Wansong Chen (CSU: Central South University)H-Index: 20
#2Jiang Ouyang (CSU: Central South University)H-Index: 17
Last. Shaojun Guo (PKU: Peking University)H-Index: 118
view all 11 authors...
: Transition-metal dyshomeostasis is recognized as a critical pathogenic factor at the onset and progression of neurodegenerative disorder (ND). Excess transition-metal ions such as Cu2+ can catalyze the generation of cytotoxic reactive oxygen species and thereafter induce neuronal cell apoptosis. Exploring new chelating agents, which are not only capable of capturing excess redox-active metal, but can also cross the blood-brain barrier (BBB), are highly desired for ND therapy. Herein, it is dem...
143 CitationsSource
Biologics are potential new therapeutics for many diseases of the central nervous system. Biologics include recombinant lysosomal enzymes, neurotrophins, decoy receptors, and therapeutic antibodies. These are large molecule drugs that do not cross the blood–brain barrier (BBB). All classes of biologics have been tested, without success, in clinical trials of brain disease over the last 25 years. In none of these past clinical trials was the biologic re-engineered to enable transport across the B...
69 CitationsSource
Cited By0